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Cell proliferative activity has been extensively investigated in head and neck tumors. Ki67/MIB-1
immunostaining, tritiated thymidine or bromodeoxyuridine labeling indices, DNA S-phase fraction,
proliferating cell nuclear antigen expression, potential doubling time and analysis of the nucleolar
organizer region associated proteins (AgNORs) have shown significant correlation with prognosis in
4806 cases of tumors of the oral cavity, salivary glands, pharynx and larynx. However, this was not
observed in 2968 other reported cases. Discrepancies may depend on various factors: the heterogen-
eity of the series, which include tumors from various anatomic sites and patients treated with differ-
ent therapy, and the lack of standardization of methods for assessing cell proliferation. Furthermore,
none of the methods currently applied can by themselves define the actual proliferative activity, as it
depends both on the proportion of cells committed to the cycle (growth fraction) and the speed of
the cell cycle. Indeed, the actual proliferative activity of a tumor could well be measured by the
equation [PA = Ki67 or MIB-1 scoresAgNORs], as we did in pharyngeal carcinoma. Provided
that large and homogeneous series are evaluated by standardized methods, cell proliferative activity
can still be regarded as an inexpensive and reliable prognostic factor in head and neck tumors.
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Introduction
Cell proliferation is regarded as one of the most important bio-
logical mechanisms in oncogenesis [1]. A survey of the results
of a large number of studies has shown that proliferative
activity is of high prognostic significance in several types of
cancer [2]. A Medline-based search (PubMed of the National
Library of Medicine, via Internet) up to July 2003 selected
6305 reports containing the terms ‘proliferative activity and
tumor’; 4373 reports containing the terms ‘proliferative
activity’ and ‘tumor diagnosis’, and 1005 containing the terms
‘proliferative activity’ and ‘tumor prognosis’.
Cell proliferation has also been extensively investigated in
head and neck tumors: up to July 2003, 306 papers have been
published on the proliferative activity in tumors of the oral
cavity, salivary glands, pharynx and larynx.
The aim of this review is to discuss and summarize the
results obtained so far as to the proliferative activity of head
and neck tumors, in an effort to verify if cell proliferation can
really provide useful prognostic information in these tumors
or not.
Proliferation markers in tumor pathology
Proliferation markers can be classified into three main cate-
gories: (i) growth fraction markers; (ii) markers of specific
phases of the cell cycle; and (iii) cell cycle time markers. The
growth fraction, i.e. the proportion of the cells committed to
the cycle, may be easily assessed by Ki-67 or MIB-1 anti-
bodies, which identify an antigen expressed in G1, S and G2
phases of cycling cells [3, 4]. The M-phase can be evaluated
by counting the mitotic figures: this is the oldest and, prob-
ably, the most popular way of assessing proliferation, even if
strict morphological criteria for the recognition of mitotic
figures are required [5]. S-phase fraction (SPF) can be
assessed by incorporation techniques, such as the in vivo or
in vitro incorporation with tritiated thymidine (TH3) or bro-
modeoxyuridine (BrdU), which can be regarded as the ‘gold
standard’ marker of S-phase cells [1]. SPF can also be
detected by static or flow cytometry (FCM) analysis of the
DNA, or the immunohistochemical detection of proliferating
cell nuclear antigen (PCNA/Cyclin), a nuclear protein
involved in DNA synthesis [6]. The very reliable punctuated
labeling of PCNA is identical to the labeling pattern obtained
with BrdU [7] and is the method of choice of evaluating the
S-phase index in histopathology [8]. Cell cycle time can be
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Table 1. Cell proliferative activity in oral cavity carcinoma
Parameter Reference No. of cases Response
Prognostic value
Ki67/MIB-1 immunostaining Girod et al. [41] 216 Survival
Matsumoto et al. [42] 20 N
Sittel et al. [34] 56 DFS
Xie et al. [43]a 85 DFS
PCNA immunostaining Storkel et al. [44]a 100 Grade, survivalb
Alcalde et al. [45] 33 T, N
Gasparini et al. [36]a 73 OSb, DFS
Tsai and Jin [46] 38 T
Daniele et al. [47] 54 N
Welkoborsky et al. [48]a 42 OSb, DFS
Sakurai et al. [49] 36 T, N, OS
TH3/BrdU-LI/Tpot Chauvel et al. [50]
a 87 OSb
Hemmer [51] 33 T, N
Mukhopadhyay et al. [52] 27 Grade, T, N
Veneroni et al. [14]a 69 OSb
Corvo` et al. [33] 35 DFS
DNA-SPF Gomez et al. [53]a 38 OSb
Oya and Ikemura [54]a 79 Nb
AgNORs Sano et al. [55] 39 OS
Hirsch et al. [56] 66 Stage
Teixeira et al. [57]a 43 DFSb
Chatterjee et al. [58] 39 Grade, T
Piffko et al. [15]a 80 OSb, DFSb
Piffko et al. [59]a 94 Metastasisb,OSb
Xie et al. [60]a 51 OSb, DFSb
Xie et al. [61]a 80 DFSb
Total 1613
No prognostic value
Ki67/MIB-1 immunostaining Roland et al. [23]a 79 OS, N
Valente et al. [28]a 31 DFS
Gonzalez-Moles et al. [62] 74 OS
Piffko et al. [63]a 100 OS
Stoll et al. [64] 107 OS, DFS
Bettendorf and Herrmann [65] 329 T, N, OS
Carinci et al. [66]a 25 OS
Okamoto et al. [67] 59 N
PCNA immunostaining Sommer and Olofsson [68] 64 T, N, DFS, OS
Sittel et al. [34] 56 DFS
TH3/BrdU-LI/Tpot Cooke et al. [22] 105 T, N, OS
Costa et al. [35]a 100 DFS
DNA-SPF Mohr et al. [20] 142 OS
Total 1271
aStudies with multivariate analysis.
bStudies in which the proliferative activity has prognostic significance in multivariate analysis.
DFS, disease-free survival; N, N stage; OS, overall survival; T, T stage.
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evaluated by the potential doubling time (Tpot), a procedure
that requires in vivo intravenous BrdU infusion and bivariate
FCM [9], or by the quantification of the argyrophilic proteins
associated with the nucleolar organizer regions (AgNORs),
loops of DNA which transcribe to ribosomal RNA [10].
AgNOR proteins can be easily detected on routinely fixed and
paraffin embedded tissues [11]. The AgNOR quantity is
strictly related to the rapidity of cell proliferation: the higher
the AgNOR quantity, the shorter the doubling time [12, 13].
Oral cavity carcinoma
A large number of papers, reporting a total of 1613 cases,
have shown the prognostic value of cell proliferation in squa-
mous cell carcinoma (SCC) of the oral cavity. In general, a
high proliferative activity is associated with poor prognosis,
even if one series of 69 oral/oropharyngeal SCC patients, who
were treated with surgery alone, reported a high TH3-LI
(where LI is labeling index) associated with a better prognosis
[14]. Almost 30% of the cases (492 of 1613) were investigated
using AgNOR analysis, even if this method of assessing cell
proliferation is not extensively applied to tumor pathology. Of
particular interest are the results obtained by Piffko et al. [15]
in 80 SCC patients, where the quantity of AgNORs at the
invasive front of the tumor was reported to be the most signifi-
cant independent prognostic factor. This finding not only pro-
vides a functional background to the well-established clinical
relevance of the histopathological tumor front grading [16],
but also suggests the use of an aggressive surgical approach
for those patients with a high AgNOR quantity. However, in a
large number of papers, reporting a total 1271 cases, cell
proliferative activity in oral SCC lacks any prognostic value.
Literature reports are summarized in Table 1.
Curiously, we noted no paper reporting a lack of prognostic
significance for AgNOR analysis. This might well imply that
Table 2. Cell proliferative activity in salivary gland tumors
Parameter Reference No. of cases Response
Prognostic value
Ki67/MIB-1 immunostaining Skalova et al. [69] 33 DFS, OS, grade
Skalova et al. [70] 30 Recurrence
Hellquist et al. [71] 32 OS
Nordgard et al. [72]a 44 DFSb
Yin et al. [73] 71 OS, grade
Okabe et al. [74]a 31 OS, grade
Xin and Paulino [75] 18 Grade, metastasis
PCNA immunostaining Batsakis [40]a 43 OSb
Cho et al. [76] 30 OS, DFS
DNA-SPF Greiner et al. [77] 45 OS
Hicks et al. [78]a 48 OSb
Franzen et al. [79]a 51 DFSb
Pinto et al. [80] 26 Grade
Junquera et al. [81] 44 T, DFS
AgNORs Chomette et al. [82] 17 OS, DFS
Chomette et al. [83] 31 OS, DFS
Vuhahula et al. [84] 34 Metastasis
Xie et al. [85]a 37 DFSb
Total 665
No prognostic value
PCNA immunostaining Felix et al. [86]a 30 OS
DNA-SPF Timon et al. [87]a 45 Recurrence, N, OS
Felix et al. [86]a 30 OS
AgNORs Fonseca and Soares [88] 18 Metastasis, OS
Timon et al. [87]a 45 Recurrence, N, OS
Total 168
aStudies with multivariate analysis.
bStudies in which the proliferative activity has prognostic significance in multivariate analysis.
DFS, disease-free survival; N, N stage; OS, overall survival; T, T stage.
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the rapidity of cell proliferation, as assessed by AgNOR
quantification, is probably the kinetic parameter which corre-
lates better with the outcome of oral cavity SCC.
Salivary gland tumors
A lot of papers, reporting a total of 665 cases, have shown
that high proliferative activity is associated with a worse prog-
nosis in salivary gland tumors of various histological type. In
particular, high AgNOR counts were indicators of poor overall
survival (OS) and/or disease-free survival (DFS) in 119 cases
from four different series. Three authors, however, reporting a
total of 168 cases, did not confirm the prognostic value of cell
proliferation in salivary gland tumors. A summary of the
reports in the literature is shown in Table 2.
Pharyngeal carcinoma
To the best of our knowledge, literature reports few papers
that have investigated the cell proliferative activity of pharyn-
geal carcinoma. Eight, for a total of 451 cases, show an
association between cell proliferation and prognosis in pharyn-
geal carcinoma. However, five other authors, for a total of 317
cases, did not confirm the prognostic value of cell prolifer-
ation. The results of the literature are shown in Table 3.
Laryngeal carcinoma
Cell proliferation evaluation has been used most extensively in
the investigation of laryngeal carcinomas, and a large number
of publications, reporting a total of 2077 cases, have shown its
prognostic value. In general, high proliferative activity is
associated with a worse prognosis, even if high Ki67 scores
were associated with a favorable response to radiotherapy in
one series of 36 T2 laryngeal cancers [17], and a low DNA-SPF
was found to predict recurrence in 23 glottic carcinomas that
achieved complete local remission after curative radiotherapy
[18]. However, a few studies, reporting a total of 1212 cases,
failed to demonstrate the prognostic value of cell proliferative
activity in laryngeal carcinoma. Table 4 shows a summary of
the literature reports.
Personal findings
A total of 94 cases of pharyngeal carcinoma were retrospec-
tively investigated in our laboratory. Patient age ranged from
29 to 87 years (mean, 60.1 years) of which 68 were male
and 26 female. Forty-two carcinomas were from the oro-
rhinopharynx and 52 from hypopharynx-pyriform sinus. All
cases were squamous cell carcinoma; according to UICC [19],
34 were grade 2 and 60 grade 3; 12 were stage T1, 25 T2, 36
T3 and 21 T4; 43 were N0, 18 N1, 5 N2 and 28 N3. Out of
42 oro-rhinopharyngeal carcinomas, 10 (23.8%) were stages
1–2 and 32 (76.2%) stages 3–4. Out of 52 hypopharynx-pyri-
form sinus carcinomas, seven (13.5%) were stages 1–2 and
45 (86.5%) stages 3–4. After diagnosis, all patients underwent
only external 60Co radiotherapy. A minimum follow-up of
3 years for censored (surviving) patients or until death was
available in all cases. Initial biopsies, fixed in 10% formalin
and embedded in paraffin, were stained with the AgNOR
Table 3. Cell proliferative activity in pharyngeal carcinoma
Parameter Reference No. of cases Response
Prognostic value
Ki67/MIB-1 immunostaining Pich et al. [89]a 28 OSb
Raybaud et al. [31]a 56 Recurrenceb
PCNA immunostaining Pich et al. [26] 45 OS
TH3/BrdU-LI/Tpot Chauvel et al. [50]
a 87 OSb
Corvo` et al. [21] 31 Recurrence
Benazzo et al. [90] 52 N
DNA-SPF Myers et al. [91] 91 OS, N, grade
AgNORs Pich et al. [25]a 61 OSb
Total 451
No prognostic value
Ki67/MIB-1 immunostaining Roland et al. [23]a 79 Metastasis, OS
Shnayder et al. [92] 54 Recurrence OS
BrdU-LI/Tpot Bourhis et al. [29]
a 70 Recurrence T, N, DFS, OS
DNA-SPF Del Valle-Zapico et al. [93]a 51 T, OS
AgNORs Pak et al. [37]a 63 OS, DFS
Total 317
aStudies with multivariate analysis.
bStudies in which the proliferative activity has prognostic significance in multivariate analysis.
DFS, disease-free survival; N, N stage; OS, overall survival; T, T stage.
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method [11] and PCNA and MIB-1 immunostaining using
PC10 and MIB-1 monoclonal antibodies.
In carcinomas of the oro-rhinopharynx, the median AgNOR
count was 10.32 AgNORs/cell and the median PCNA score
36.12. No association was found between AgNOR counts or
PCNA scores and tumor histological grade or stage.
The median OS for the whole series was 48 months, and the
3- and 5-year survival rates were 60% and 49%, respectively.
Cell proliferation was the only significant prognostic factor:
using the median values as the cut-off, 3-year survival rates
Table 4. Cell proliferative activity in laryngeal carcinoma
Parameter Reference No. of cases Response
Prognostic value
Ki67/MIB-1 immunostaining Hake et al. [94] 47 Recurrence, DFS
Welkoborsky et al. [95]a 40 Recurrenceb
Franchi et al. [96]a 60 Nb
Kropveld et al. [17] 36 Recurrence
Golusinski et al. [97] 120 T, N, grade
Valente et al. [98]a 102 DFSb
Sittel et al. [38] 47 Recurrence, DFS
Lazaris et al. [99]a 96 Recurrence, Nb
Wozniak et al. [100] 55 T, N
PCNA immunostaining Munck-Wikland et al. [27] 28 Recurrence
Welkoborsky et al. [95]a 40 OSb
Franchi et al. [96]a 60 Nb
Dobros et al. [101] 90 N, OS
Krecicki and Jelen [102]a 154 OSb
Sarac et al. [103]a 92 Grade, N, DFSb
Dong et al. [104]a 54 OS, DFS
Sittel et al. [38] 47 Recurrence, DFS
Dong et al. [105] 102 OS
BrdU-Tpot Alsner et al. [32] 58 OS
DNA-SPF Tennvall et al. [18] 23 Recurrence
Tomasino et al. [106]a 99 OSb, DFSb
Danic et al. [107]a 36 OSb
Myers et al. [91] 91 OS, Grade, N
Dobros et al. [108]a 90 OSb
Bazan et al. [109]a 64 OS
AgNORs Bockmuhl et al. [110]a 30 OSb, DFSb
Xie et al. [111]a 93 DFSb
Xie et al. [112] 69 DFS
Krecicki et al. [113]a 154 OSb
Total 2077
No prognostic value
Ki67/MIB-1 immunostaining Roland et al. [23]a 79 N, OS
Resnick et al. [24] 88 N, OS
Spafford et al. [114]a 70 Metastasis, OS
Hirvikoski et al. [115]a 103 DFS, OS
Pulkkinen et al. [116]a 100 OS
Krecicki et al. [117]a 154 T, N
PCNA immunostaining Resnick et al. [24] 88 N, OS
Tomasino et al. [106]a 99 OS, DFS
Hirvikoski et al. [115]a 103 DFS, OS
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were 81% for patients with <_10.32 AgNORs/cell but only
38% for those with higher counts (P = 0.0002); 87% for
patients with PC10 scores <_36.12, but only 40% for those
with higher scores (P = 0.0002). In Cox multivariate survival
analysis, only PCNA appeared as an independent variable
(x2 = 13.56; P < 0.001; rr = 8.16). When PCNA was excluded,
AgNOR count emerged as an independent variable
(x2 = 13.79; P < 0.001; rr = 5.71).
In carcinomas of the hypopharynx-pyriform sinus, the
median AgNOR count was 11.27 AgNORs/cell and the
median PCNA score 40. No association was found between
AgNOR counts or PCNA scores and tumor histological grade
or stage. The median MIB-1 score was 33.87 and was higher
in G3 than in G2 carcinomas (P = 0.008). The median OS for
the whole series was 20 months, and the 3- and 5-year survi-
val rates were 26% and 22%, respectively. Of the classical
parameters, histological grade (P = 0.009) and T stage
(P = 0.04) were associated with OS. Using the median values
as a cut-off, the 3-year survival rates were 48% for patients
with <_11.27 AgNORs/cell, but only 4% for those with higher
counts (P <0.0001); 71% for patients with PC10 scores <_40
but only 14% for those with higher scores (P = 0.01); 47% for
patients with MIB-1 scores <_33.87 and 0% for those with
higher counts (P <0.0001). In Cox multivariate survival analy-
sis, only MIB-1 scores (x2 = 18.53; P <0.001; rr = 6.06) and
AgNOR counts (x2 = 3.89; P = 0.04; rr = 3.34) appeared as
independent prognostic variables.
Comments
Even if most of the papers published to date show a corre-
lation between high proliferative activity and poor prognosis
in head and neck tumors, a large number of reports failed to
show any significant association with prognosis. There are
several reasons which may account for this discrepancy.
Anatomic site
In the last edition of the TNM classification of malignant
tumors [19], head and neck tumors include tumors of the lip,
oral cavity, pharynx, larynx, maxillary sinus, nasal cavity and
ethmoid sinus, salivary gland and thyroid gland. Therefore,
the series which generically deal with tumors of the ‘head and
neck’ [20–23] are heterogeneous, mixing tumors of different
histological type, biological activity and, consequently, clini-
cal behavior. Our experience with pharyngeal carcinoma indi-
cates that it is better not to consider pharyngeal tumors from
different anatomic sites as a whole. In fact, the median OS was
23 months when the whole series of 94 cases was considered;
however, when cases were subdivided according to the ana-
tomic site, the median OS of the 42 oro-rhinopharyngeal car-
cinomas was 48 months, significantly longer than that of the
52 hypopharynx-pyriform sinus cases (20 months, P = 0.002).
The different survival rates were not dependent on differences
in clinical stage, since the proportion of low and advanced
cases was comparable in the two anatomic sites (P = 0.3).
Type of therapy
Literature reports some series of head and neck tumors treated
with surgery alone [14, 24], and others with radiotherapy
alone [18, 21, 25–32]. Other series were treated with com-
bined surgery and radiotherapy [33, 34], combined surgery
and chemotherapy [35], or combined radio- and chemotherapy
[36, 37], and there were also a few cases treated with laser
therapy [38]. Since different therapies, especially chemo- or
radiotherapy, interfere with biological tumor activities, only
homogeneously treated series of head and neck carcinomas
should be compared if the prognostic value of cell proli-
feration is to be assessed reliably. For instance, TH3-LI pro-
vided independent prognostic information in oral and
oropharyngeal carcinomas treated with surgery alone [14],
but did not appear to be a predictive factor in patients with
carcinoma of the same anatomic site submitted to primary
chemotherapy followed by surgery [35].
Standardization
There is a lack of standardization in the various methods for
assessing cell proliferation. The number of mitotic figures can
be evaluated in several ways: (i) the mitotic index (MI) (total
number of mitoses in 10 high power fields); (ii) the mitotic
rate (MR) (number of mitoses per 1000 cells); or (iii) the
number of mitoses for the area percentage of epithelium,
which yields the mitoses per volume (M/V) index [1]. Of
course, the different procedures lead to different mitosis
Table 4. (Continued)
Parameter Reference No. of cases Response
DNA-SPF Resnick et al. [24] 88 N, OS
AgNORs Yamamoto et al. [118] 73 OS
Barnes et al. [119] 53 T, N, recurrence, OS
Pulkkinen et al. [120] 66 DFS, OS
Klatka and Skomra [121] 48 T, N, OS
Total 1212
aStudies with multivariate analysis.
bStudies in which the proliferative activity has prognostic significance in multivariate analysis.
DFS, disease-free survival; N, N stage; OS, overall survival; T, T stage;
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counts. The use of various antibody dilutions, or antigen
retrieval, can lead to different results in immunohistochemical
staining e.g. most of our PC10 immunonegative pharyngeal
carcinomas became positive after microwave irradiation.
Moreover, different DNA indices and SPF values are obtained
when fresh or fixed tissues are processed. Lastly, the positivity
or negativity of a case may depend on the different cut-off
values of the proliferation markers. For instance, we chose the
median MIB-1 value (33.87) as a cut-off in our series of hypo-
pharyngeal carcinomas and found 14 (50%) negative cases;
however, only between one and three cases would have been
negative if a cut-off of 15–20% (similar to the cut-off cur-
rently used for mammary carcinomas) had been applied.
Site of measurement
The site of measurement is another point, as heterogeneity is
one of the hallmarks of malignancy, and heterogeneity for
several proliferation markers has been documented for many
types of tumors. A large tumor specimen may be classified
positive or negative depending on whether the proliferation
markers are evaluated only at the most ‘active’ sites (e.g. the
invasive tumor front) [15], in randomly selected areas [25, 26]
or in the maximally positive tumor field [17].
Identification of neoplastic cells
There is a difficulty in identifying the neoplastic cells. It is
often hard to distinguish by MIB-1 or PCNA immunostaining
small neoplastic cells from reactive proliferating lymphocytes
in poorly differentiated rhinopharyngeal carcinomas. AgNOR
staining is particularly suitable in such cases, since it allows
for an easy distinction between neoplastic and non-neoplastic
cells, avoiding the need for double (Citokeratin/MIB-1)
staining.
Proliferative activity
Finally, what was indeed measured in most studies reported is
not the actual proliferative activity of a tumor, in as much as
the mechanisms responsible for proliferative activity are the
proportion of cells committed to cycle (growth fraction, or G)
and the speed of the cycle, which is inversely proportional to
the generation time (T) [1]. The mathematical relationship
between proliferative activity (PA), growth fraction (G) and
generation time (T) is PA = G/T [1]. It is clear from this
equation that neither the growth fraction nor the generation
time can by itself define the actual proliferative activity of a
tumor [39]. The tumor growth fraction can be easily assessed
on routinely processed tissues by the Ki67 or MIB-1 labeling
index, since Ki67 or MIB-1 antibodies recognize an antigen
expressed in all cycling cells [3, 4]. On the contrary, evalu-
ation of the speed of cell cycle by the potential doubling time
(Tpot) is a rather lengthy procedure and is not suitable for ret-
rospective studies. However, since the AgNOR quantity
reflects the rapidity of cell proliferation [12, 13], and can be
detected in routinely fixed and embedded tissues [11],
AgNOR analysis can be regarded as an easy and reliable tech-
nique to evaluate the tumor cell doubling time on histological
preparations. Therefore, the ‘actual’ proliferative activity of a
tumor can be simply expressed by the equation (PA = Ki67 or
MIB-1 scoresAgNOR quantity). To the best of our know-
ledge, this equation, which represents the ‘true’ proliferative
activity of a tumor, has never been applied to head and neck
tumors. We used this formula to assess cell proliferation in 28
carcinomas of the hypopharynx-pyriform sinus. The median
OS for the whole series was 18 months, and the 3- and 5-year
survival rates were 24% and 19%, respectively. Using the
median (MIB-1AgNOR) value as a cut-off, the median
survival for cases with (MIB-1AgNOR) <_407.61 was
23 months, but only 11 months for those with higher values
(P <0.0001). Noteworthy, after 20 months of follow-up, 79%
of patients with a low (MIB-1AgNOR) index were alive,
whereas patients with higher values were not (Figure 1). We
are aware that the number of our cases is rather small and this
approach should be validated in a large series of patients.
Summary
Despite the many negative reports in the literature, cell proli-
ferative activity is a reliable prognostic factor in head and
neck tumors, especially when studies are performed with
well standardized methods that take into account the type of
treatment used. Indeed, a high cell proliferation, as expressed
by the MIB-1 labeling index, was a significant indicator for
treatment failure in a large matched-pair study design of
recurrent and non-recurrent oral and oropharyngeal carci-
nomas initially treated with primary surgery combined with
curative post-operative radiation [34]. Also, in another large
matched-pair study on recurrent and non-recurrent laryngeal
carcinomas, homogeneous for site (glottis), stage (T1 and T2)
and treatment (transoral laser surgery alone), investigated
using well standardized MIB-1 and PCNA staining and
scoring, high proliferative activity appeared to be a signifi-
cant prognostic factor. Lastly, the standardized AgNOR ana-
lysis showed the strong independent prognostic value of
cell proliferation in a large series of oral squamous cell carci-
noma [15].
Figure 1. Kaplan–Meier survival curves (OS) for 28 hypopharynx-
pyriform sinus carcinomas categorized according to the median
(MIB-1AgNOR) value.
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An increasing number of sophisticated techniques, such as
molecular biology, are currently being applied to tumor path-
ology to investigate the oncogene alterations responsible for
cell proliferation changes. However, since the proliferation
changes during the cell cycle reflect the net effect of genetic
damage and, therefore, include the accumulated changes in
genes, they may be regarded as more useful prognostic indi-
cators than individual oncogene alterations [40].
In conclusion, provided that large series of cases, homo-
geneous for anatomic site and type of treatment, are evaluated
by well standardized methods, cell proliferative activity still
seems to be an inexpensive and reliable prognostic factor in
head and neck tumors.
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